F
Fahad Al-Hameed
Researcher at King Saud bin Abdulaziz University for Health Sciences
Publications - 63
Citations - 3231
Fahad Al-Hameed is an academic researcher from King Saud bin Abdulaziz University for Health Sciences. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 18, co-authored 55 publications receiving 2610 citations. Previous affiliations of Fahad Al-Hameed include National Guard Health Affairs & King Abdulaziz Medical City.
Papers
More filters
Journal ArticleDOI
Corticosteroid Therapy for Critically Ill Patients With Middle East Respiratory Syndrome
Yaseen M. Arabi,Yasser Mandourah,Fahad Al-Hameed,Anees Sindi,Ghaleb A. Almekhlafi,Mohamed A. Hussein,Jesna Jose,Ruxandra Pinto,Awad Al-Omari,Ayman Kharaba,Abdullah Almotairi,Al Khatib K,Basem Alraddadi,Sarah Shalhoub,Ahmed Abdulmomen,Ismeal Qushmaq,Ahmed Mady,Othman Solaiman,Abdulsalam M. Al-Aithan,Rajaa Al-Raddadi,Ahmed Ragab,Hanan H. Balkhy,Al Harthy A,Ahmad M. Deeb,Al Mutairi H,Abdulaziz Al-Dawood,Laura Merson,Frederick G. Hayden,Frederick G. Hayden,Rob Fowler +29 more
TL;DR: Corticosteroid therapy in patients with MERS was not associated with a difference in mortality after adjustment for time‐varying confounders but was associated with delayed MERS coronavirus RNA clearance.
Journal ArticleDOI
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
Yaseen M. Arabi,Yaseen M. Arabi,Yaseen M. Arabi,Adel Alothman,Adel Alothman,Hanan H. Balkhy,Hanan H. Balkhy,Abdulaziz Al-Dawood,Abdulaziz Al-Dawood,Sameera Aljohani,Sameera Aljohani,Shmeylan Al Harbi,Shmeylan Al Harbi,Suleiman Kojan,Suleiman Kojan,Majed Al Jeraisy,Majed Al Jeraisy,Ahmad M. Deeb,Ahmad M. Deeb,Abdullah M. Assiri,Fahad Al-Hameed,Fahad Al-Hameed,Asim Alsaedi,Asim Alsaedi,Yasser Mandourah,Ghaleb A. Almekhlafi,Nisreen Murad Sherbeeni,Fatehi Elnour Elzein,Javed Memon,Yusri Taha,Abdullah Almotairi,Khalid Maghrabi,Ismael Qushmaq,Ali Al Bshabshe,Ayman Kharaba,Sarah Shalhoub,Jesna Jose,Robert A. Fowler,Robert A. Fowler,Frederick G. Hayden,Mohamed A. Hussein +40 more
TL;DR: The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.
Journal ArticleDOI
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.
Yaseen M. Arabi,Sarah Shalhoub,Yasser Mandourah,Fahad Al-Hameed,Awad Al-Omari,Eman Al Qasim,Jesna Jose,Basem Alraddadi,Abdullah Almotairi,Kasim Al Khatib,Ahmed Abdulmomen,Ismael Qushmaq,Anees Sindi,Ahmed Mady,Ahmed Mady,Othman Solaiman,Rajaa Al-Raddadi,Khalid Maghrabi,Ahmed Ragab,Ghaleb A. Al Mekhlafi,Hanan H. Balkhy,Abdulrahman Al Harthy,Ayman Kharaba,Jawaher Gramish,Abdulsalam M. Al-Aithan,Abdulaziz Al-Dawood,Laura Merson,Frederick G. Hayden,Frederick G. Hayden,Robert A. Fowler +29 more
TL;DR: RBV/rIFN therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance.
Journal ArticleDOI
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Yaseen M. Arabi,Yaseen M. Arabi,Ali H. Hajeer,Thomas C. Luke,Kanakatte Raviprakash,Hanan H. Balkhy,Hanan H. Balkhy,Hanan H. Balkhy,Sameera M. Al Johani,Abdulaziz Al-Dawood,Saad Al-Qahtani,Awad Al-Omari,Fahad Al-Hameed,Fahad Al-Hameed,Frederick G. Hayden,Frederick G. Hayden,Robert A. Fowler,Abderrezak Bouchama,Nahoko Shindo,Khalid Al-Khairy,Gail Carson,Yusri Taha,Musharaf Sadat,Mashail Alahmadi +23 more
TL;DR: Efficacy testing will be challenging because of the small pool of donors with sufficiently high antibody titers.
Journal ArticleDOI
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.
Yaseen M. Arabi,Hanan H. Balkhy,Ali H. Hajeer,Abderrezak Bouchama,Frederick G. Hayden,Awad Al-Omari,Fahad Al-Hameed,Yusri Taha,Nahoko Shindo,John Whitehead,Laura Merson,Sameera Aljohani,Khalid Al-Khairy,Gail Carson,Thomas C. Luke,Lisa E. Hensley,Abdulaziz Al-Dawood,Saad Al-Qahtani,Kayvon Modjarrad,Musharaf Sadat,Gernot Rohde,Catherine Leport,Robert A. Fowler +22 more
TL;DR: This study aims to study the feasibility of convalescent plasma (CP) therapy as well as its safety and clinical and laboratory effects in critically ill patients with MERS-CoV infection, and will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MSPV infection.